Faculty – Digital Therapeutics Summit

Veera Anantha
Founder, CTO and President, THE LEARNING CORP

view speaker profile

Dr. Veera Anantha is a hands-on technology executive and business leader with a passion to positively change the world using technology and AI. He has held executive positions at Fortune 100 companies; and has successfully founded, led & grown startups resulting in significant exits (to Apple, Motorola, West Health). Dr. Anantha is currently President & Co-Founder of The Learning Corp, creator of the award winning Constant Therapy app that uses AI to help people recover their brain function after a stroke, brain injury or other neurological disorders. Dr. Anantha grew Constant Therapy quickly from an idea to a high impact digital health product serving tens of thousands of patients and clinicians globally. Constant Therapy has won awards from the American Heart Association and AARP for its patient impact.

Previously as an executive at Motorola, Dr. Anantha led a global team that created several award winning enterprise wireless products and brought them to market worldwide. As VP Engineering at Wireless Valley (a startup acquired by Motorola), he led a team that invented wireless technologies that are used around the world to design and manage complex wireless networks (most wireless routers in buildings and campuses work well today because to this ubiquitous technology). While at Intrinsity (a startup acquired by Apple), Dr. Anantha worked with a team that built the world’s fastest Digital Signal Processor at the time.

Dr. Anantha has a MS and Ph.D. from Northwestern University and BS from the Indian Institute of Technology (IIT), Mumbai. He holds several technology patents, is an author on many peer-reviewed scientific papers, and a frequent speaker at technology & digital health forums and conferences. Dr. Anantha is a mentor at MassChallenge, Insight Health Data Science, and is Charter Member of TiE Boston.

Mark Bini
Vice President, Innovation and Member Experience, EXPRESS SCRIPTS

view speaker profile

Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for the development of Express Scripts’ suite of digital health solutions that includes remote monitoring solutions for diabetes, asthma, medication non-adherence among others. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.

Edward Cox

Martin Culjat
SVP Scientific and Regulatory Affairs, DTHERA SCIENCES

view speaker profile

Martin Culjat, Ph.D. is SVP of Scientific & Regulatory Affairs at Dthera Sciences. Dr. Culjat has almost 20 years of experience developing innovative medical devices and digital health products, both in academia and in startups. At Dthera, he led the effort to obtain the first ever Breakthrough Device designation from the FDA for a digital therapeutic monotherapy. He holds a B.S. in Bioengineering from UC San Diego and Ph.D. and M.S. degrees in Biomedical Engineering from UCLA.

Savan Devani

view speaker profile

Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing a platform called BioEngine4D for data-driven drug development and to digitally detect developing diseases.

Savan previously spent the majority of his 15-year career as a healthcare investment banker with Citigroup and Deutsche Bank. From Analyst through Managing Director, Savan completed 40 financing and M&A deals, totaling $35 billion in deal value, with clients across the drug, diagnostic, and device spectrum. He began his career as a bioengineer at Life Technologies.

Savan graduated with a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania.

After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was abruptly diagnosed with stage 4b cancer. This compelled Savan to ask “where were all the signs” and “isn’t there a better way,” which led him back to his Bioengineering roots by founding BioTrillion

Mette Dyhrberg
Founder and CEO, MYMEE

Barbara Eichorst, M.S., RD, CDE
Global Diabetes and Digital Therapeutics Clinical Liaison, VOLUNTIS

view speaker profile

Barbara is a Clinical Diabetes Liaison at Voluntis. Previously, she has been a Vice President of Clinical Care responsible for leading a global patient-centric self-management education of 126 countries. Barbara’s experience from the last 20 years include working with a national insulin titration initiative; directing provider and approver units at American Association of Diabetes Educators; managing diabetes education program at Rush University Medical Center; and providing patient care at Chicago based academic institutions such as Loyola University Medical Center and Northwestern Memorial Hospital. Barbara’s professional focus is on behavioral interventions in disease management, insulin titration and digital therapeutics. She has contributed to multiple publications, public speaking, and key opinion leadership with her expertise in diabetes patient/provider engagement, self-management education, insulin titration and digital therapeutics.

Laurel Fuqua, RN, MSN
Executive Vice President and Chief Clinical Officer, MONARCH MEDICAL TECHNOLOGIES

view speaker profile

Laurel Fuqua joined Monarch Medical Technologies in 2017 as Executive Vice President and Chief Clinical Officer. As an accomplished executive and diabetes industry leader, Laurel draws from more than three decades of healthcare experience to lead the clinical vision and guide the product strategy at Monarch.

She has held executive-level positions across a wide range of healthcare settings including, hospitals, health plans, care management, and diabetes technology firms. Prior to joining the company, Laurel served as the Senior Vice President of Clinical and Operations at Canary Health, a provider of digital health self-management programs. Previously, she was the Senior Vice President of Population Health, Clinical Affairs & Care Innovations for InSpark Technologies. She also has held executive positions with Glytec, Alere, Inspiris, Kindred Healthcare, and Healthways, among others.

Laurel is frequently invited to speak on improving the safety of glucose management and regularly authors industry articles. She has received several accolades for her work, including the AADE Diabetes Educator of the Year Award early in her career. Laurel received her bachelor of science and master of science in nursing from the University of Evansville.

Jennifer Goldsack, MChem, MA, MBA, OLY
Interim Executive Director, DIGITAL MEDICINE SOCIETY

view speaker profile

Jen Goldsack leads Strategy, Portfolio and Operations at HealthMode and serves as the Interim Executive Director of the Digital Medicine Society (DiMe). Previously, Jen spent several years at the Clinical Trials Transformation Initiative (CTTI) where she led development and implementation several projects within CTTI’s Mobile Program and was the operational co-lead on the first randomized clinical trial using FDA’s Sentinel System.

Jen spent five years working in research at the Hospital of the University of Pennsylvania, first in Outcomes Research in the Department of Surgery and later in the Department of Medicine. More recently, she helped launch the Value Institute, a pragmatic research and innovation center embedded in a large academic medical center in Delaware. Jen earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality. Ms Goldsack is a retired athlete, formerly a Pan American Games Champion, Olympian and World Championship silver medalist.

Vincent Hennemand
SVP, Corporate and Business Development, AKILI INTERACTIVE LABS

view speaker profile

At Akili Interactive Labs Mr. Hennemand is currently SVP of Strategy, Corporate & Business Development, Vincent is also leading the Immuno-Inflammation Therapeutic Unit. Prior his tenure at Akili, Vincent was previously VP Corporate Development and Operations at PureTech Health, the founding institution of Akili Therapeutic Labs.
Vincent spent a decade in Pharma at Sanofi Genzyme during which he had the opportunity to hold several positions from R&D, General Management, Manufacturing and Corporate Venture (SGBV) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio and Portal Instruments. He holds an Msc in Engineering from Ecole Nationale Superieure Arts et Metiers in France, an Msc in Bioengineering from Georgia Tech, and an MBA from MIT where he received a Martin Trust Center Fellowship.

Adam Kaufman
President and CEO, CANARY HEALTH

view speaker profile

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in digital therapeutics, patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente and Blue Shield of California to empower members to better health self-management. As CEO of Canary Health, Adam has led the company through several strategic transactions and positioned it for rapid growth in the digital health sector.
Prior to joining Canary Health as President and CEO, Adam was the General Manager of dLife’s Healthcare Solutions division. From 2009 through 2011 he served as adjunct assistant professor in the Economics Department at the University of Southern California and Chief Operating Officer of DPS Health. Adam completed his Ph.D. in Applied Economics with a focus on micro-economic models of health behavior choice from the University of Southern California. He received a B.S. in Economics from the Wharton School at the University of Pennsylvania, and a B.A.S. in Systems Engineering from the University of Pennsylvania. Upon graduating, he received a Fulbright Scholarship for work and study in Mexico.

Owen McCarthy
Co-Founder & President, MEDRHYTHMS

view speaker profile

Owen is the co-founder and President of MedRhythms Inc, a digital therapeutics company that uses sensors, music, and AI to build evidence-based neurologic interventions to measure and improve walking. He is determined to provide patients across the globe with the services necessary to recover their walking ability and regain their independence. Owen started MedRhythms as an experienced entrepreneur with an MBA degree from Harvard Business School. He also serves as the co-chair of the reimbursement working group at the Digital Therapeutics Alliance.

Kevin McRaith

view speaker profile

As President and CEO, Kevin leads the Welldoc® team in the development and commercialization of innovative digital therapeutics for people living with chronic disease. Kevin has over 25 years of experience in the life sciences sector including biotech, pharmaceuticals, health supplies and digital health. Prior to joining Welldoc, he held senior executive roles at Human Genome Sciences, Genentech and Abbott after starting his career at Baxter Healthcare.

Debra Reisenthel
Founding CEO, Freespira Digital Therapeutic, PALO ALTO HEALTH SCIENCES

view speaker profile

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

Carlos Rodarte
SVP Life Sciences Strategy and Business Development, HEALTH CATALYST

Joel Sangerman
Chief Commercial Officer, CLICK THERAPEUTICS

view speaker profile

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world. For over 25 years Joel has advanced new health technologies in the pharmaceutical industry. He is a graduate of DePaul University and a fellow of the Advisory Board Company.

Yoshinori Satomi, Ph.D.
Associate Director, Digital Intelligence Dept., SHIONOGI

view speaker profile

I joined Shionogi in April 2017 as an associate director of Digital Intelligence Department. Before Shionogi, I had been a researcher at Takeda since 2000, mostly focusing on translational research and precision medicine to improve the success of drug development by taking advantage of bioinformatics and omics technology. My current focus is on development of digital therapeutics (DTx) as a next generation therapeutic modality not just as a treatment option but also as a hub to improve patient’s life. In the interim, I’ve involved in the due diligence team of the Akili’s product, AKL-T01. Now, I work as a project member of AKL-T01/SDT-001, which stands for “Shionogi Digital Therapeutics 001”, in Japan for localization and clinical development collaborating with Akili.

Ruchita Sinha
Former Senior Director of Investments, SANOFI VENTURES

view speaker profile

Ruchita Sinha is Former Senior Director of Investments at Sanofi Ventures where she invests in biopharma and digital health opportunities. She led Sanofi’s investments in Inozyme, Omada Health, Evidation Health, Curisium, Click Therapeutics, Aetion, and also manages investments in Science 37 and Common Sensing. Prior to Sanofi, Ruchita was at GE Ventures, where she served as a board observer for HeadSense Medical and Caremerge and managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. She also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 17 years of healthcare experience in pharma, biotech, medical devices, and digital health. Previously, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company. She holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Ryan Sysko

Suzanne Sysko Clough, M.D.
Chief Medical Officer, AMALGAMRX

Matthew Tucker
Director of Strategy and Innovation, HIGHMARK HEALTH

Chris Wasden
Ed.D., Head, Pharma, HAPPIFYDTX

view speaker profile

Chris is the Head of HappifyDTx, a digital mental health therapy company that has had nearly 4 million people use its self-care digital solution to address their mental health challenges. He is the co-author of two books on innovation, creativity, and leadership: Tension – The Energy of Innovation; and Solving for Why – Change Your Identity, Change Your Future. He is the named inventor on 12 issued patents, and has been a founding leader in 10 startups, and has held leadership positions at JP Morgan and PwC. He holds a doctorate from George Washington University in Human and Organizational Learning, and an MBA from UCLA Anderson School.

Happify provides digital health interventions that, when completed 2-3 times per week for 8 weeks, have been shown, through randomized controlled trials with over 2,000 patients, to decrease the symptoms of stress, anxiety and depression and improve resilience of users by 25-30%. Our interventions are developed in partnership with leading clinical researchers and are based upon the application of evidence-based interventions from positive psychology, cognitive behavior therapy, and mindfulness. We have had nearly 4 million people use our therapy to improve their mental health and we work with pharmaceutical companies, health systems, health plans and employers to improve the mental health of their patients, members and employees. Currently we are under FDA enforcement discretion and are preparing to file with FDA for clearance of a prescription only version of our product.